https://orcid.org/0000-0003-4423-5496
References
- Duan X, Xia L, Zhang Z, et al. First-in-human study of the radioligand 68Ga-N188 targeting nectin-4 for PET/CT imaging of advanced urothelial carcinoma. Clin Cancer Res. 2023;29(17):3395–3407. doi: 10.1158/1078-0432.CCR-23-0609
- Antoni S, Ferlay J, Soerjomataram I, et al. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71(1):96–108. doi: 10.1016/j.eururo.2016.06.010
- Barone B, Calogero A, Scafuri L, et al. Immune checkpoint inhibitors as a neoadjuvant/Adjuvant treatment of muscle-invasive bladder cancer: a systematic review. Cancers. 2022;14(10):2545. doi: 10.3390/cancers14102545
- Hepp Z, Shah SN, Smoyer K, et al. Epidemiology and treatment patterns for locally advanced or metastatic urothelial carcinoma: a systematic literature review and gap analysis. J Manag Care Spec Pharm. 2021;27(2):240–255. doi: 10.18553/jmcp.2020.20285
- Bellmunt J, Orsola A, Leow JJ, et al. Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii40–8. doi: 10.1093/annonc/mdu223
- Iacovino ML, Miceli CC, De Felice M, et al. Novel therapeutic opportunities in neoadjuvant setting in urothelial cancers: a New horizon opened by molecular classification and immune checkpoint inhibitors. Int J Mol Sci. 2022;23(3):1133. doi: 10.3390/ijms23031133
- Chatterjee S, Sinha S, Kundu CN. Nectin cell adhesion molecule-4 (NECTIN-4): a potential target for cancer therapy. Eur J Pharmacol. 2021;911:174516. doi: 10.1016/j.ejphar.2021.174516
- Lattanzi M, Rosenberg JE. The emerging role of antibody-drug conjugates in urothelial carcinoma. Expert Rev Anticancer Ther. 2020;20(7):551–561. doi: 10.1080/14737140.2020.1782201
- Solnes LB, Werner RA, Jones KM, et al. Theranostics: Leveraging Molecular Imaging and Therapy to Impact Patient Management and Secure the Future of Nuclear Medicine. J Nucl Med. 2020;61(3):311–318. doi: 10.2967/jnumed.118.220665
- Filippi L, Di Costanzo GG, Tortora R, et al. Prognostic value of neutrophil-to-lymphocyte ratio and its correlation with fluorine-18-fluorodeoxyglucose metabolic parameters in intrahepatic cholangiocarcinoma submitted to 90Y-radioembolization. Nucl Med Commun. 2020;1(1):78–86. doi: 10.1097/MNM.0000000000001123
- Levine R, Krenning EP. Clinical history of the theranostic radionuclide approach to neuroendocrine tumors and other types of cancer: Historical review based on an interview of Eric P. Krenning by Rachel Levine. J Nucl Med. 2017;58(Suppl 2):3S–9S. doi: 10.2967/jnumed.116.186502
- Cimini A, Ricci M, Chiaravalloti A, et al. Theragnostic aspects and radioimmunotherapy in pediatric tumors. Int J Mol Sci. 2020;21(11):3849. doi: 10.3390/ijms21113849
- Filippi L, Bagni O, Schillaci O. Digital PET/CT with 18F-FACBC in early castration-resistant prostate cancer: our preliminary results. Expert Rev Med Devices. 2022;19(7):591–598. doi: 10.1080/17434440.2022.2117612
- Alavi A, Saboury B, Nardo L, et al. Potential and most relevant applications of total body PET/CT imaging. Clin Nucl Med. 2022;47(1):43–55. doi: 10.1097/RLU.0000000000003962
- Filippi L, Dimitrakopoulou-Strauss A, Evangelista L, et al. Long axial field-of-view PET/CT devices: are we ready for the technological revolution? Expert Rev Med Devices. 2022;19(10):739–743. doi: 10.1080/17434440.2022.2141111
- Dimitrakopoulou-Strauss A, Pan L, Sachpekidis C. Long axial field of view (LAFOV) PET-CT: implementation in static and dynamic oncological studies. Eur J Nucl Med Mol Imaging. 2023;50(11):3354–3362. doi: 10.1007/s00259-023-06222-3
- Brechbiel MW. Targeted α-therapy. Cancer Biother Radiopharm. 2020;35(6):397. doi: 10.1089/cbr.2020.29008.mbr